oncternal therapeutics, inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. the company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ror1) that is in phase i/ii clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in phase ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. it also develops tk-216, a small-molecule that is designed to inhibit e26 transformation specific family of oncoproteins, which is in phase i clinical trial to treat patients with ewing sarcoma and in combination with vincristine chemotherapy. in addition, the company develops a chimeric antigen receptor-t product candidate that targets ror1, whic
Company profile
Ticker
ONCT
Exchange
Website
CEO
James Breitmeyer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GTX INC /DE/, GTX INC/TN
SEC CIK
Corporate docs
Subsidiaries
Oncternal Oncology, Inc. • Oncternal, Inc. ...
IRS number
621715807
ONCT stock data
Latest filings (excl ownership)
S-3
Shelf registration
8 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
7 Mar 24
8-K
Entry into a Material Definitive Agreement
23 Jan 24
8-K
Results of Operations and Financial Condition
5 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
9 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Oct 23
8-K/A
Submission of Matters to a Vote of Security Holders
14 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
Transcripts
ONCT
Earnings call transcript
2023 Q4
7 Mar 24
ONCT
Earnings call transcript
2023 Q3
9 Nov 23
ONCT
Earnings call transcript
2023 Q2
10 Aug 23
ONCT
Earnings call transcript
2023 Q1
4 May 23
ONCT
Earnings call transcript
2022 Q4
9 Mar 23
ONCT
Earnings call transcript
2022 Q3
4 Nov 22
ONCT
Earnings call transcript
2022 Q2
10 Aug 22
ONCT
Earnings call transcript
2022 Q1
5 May 22
ONCT
Earnings call transcript
2021 Q4
11 Mar 22
ONCT
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 14.93 mm | 14.93 mm | 14.93 mm | 14.93 mm | 14.93 mm | 14.93 mm |
Cash burn (monthly) | 302.33 k | 4.64 mm | 3.46 mm | 3.67 mm | 1.84 mm | 2.90 mm |
Cash used (since last report) | 2.08 mm | 31.99 mm | 23.87 mm | 25.26 mm | 12.66 mm | 19.95 mm |
Cash remaining | 12.84 mm | -17.06 mm | -8.94 mm | -10.34 mm | 2.26 mm | -5.03 mm |
Runway (months of cash) | 42.5 | -3.7 | -2.6 | -2.8 | 1.2 | -1.7 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 52 |
Opened positions | 4 |
Closed positions | 6 |
Increased positions | 13 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 2.67 bn |
Total shares | 9.33 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 2.86 mm | $858.27 mm |
Millennium Management | 1.65 mm | $499.61 mm |
BLK Blackrock | 785.68 k | $235.70 mm |
Richmond Brothers | 494.04 k | $148.21 mm |
Geode Capital Management | 475.95 k | $144.38 mm |
Quantum Private Wealth | 459.19 k | $137.76 mm |
Brighton Jones | 338.49 k | $101.55 mm |
Renaissance Technologies | 313.30 k | $94.00 k |
Pasadena Private Wealth | 278.75 k | $83.63 mm |
LPL Financial | 171.46 k | $51.44 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | Wills Robert James | Common Stock | Buy | Acquire P | No | No | 8.9613 | 3,086 | 27.65 k | 10,000 |
28 Mar 24 | Wills Robert James | Common Stock | Buy | Acquire P | No | No | 8.4759 | 6,914 | 58.60 k | 6,914 |
23 Feb 24 | Hale David F | Common Stock | Buy | Acquire P | Yes | No | 9.04 | 266 | 2.40 k | 29,673 |
23 Feb 24 | Hale David F | Common Stock | Buy | Acquire P | No | No | 9.04 | 714 | 6.45 k | 714 |
23 Feb 24 | Wills Robert James | Common Stock | Sell | Dispose S | No | No | 9.04 | 980 | 8.86 k | 0 |
14 Feb 24 | Breitmeyer James B | Stock Option Common Stock | Grant | Acquire A | Yes | No | 9.18 | 6,200 | 56.92 k | 6,200 |
14 Feb 24 | Breitmeyer James B | Stock Option Common Stock | Grant | Acquire A | No | No | 9.18 | 28,400 | 260.71 k | 28,400 |
News
Oncternal Announces First Patient Dosed In Fourth Cohort Of Phase 1/2 Study Of ONCT-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer
18 Apr 24
HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $28
15 Apr 24
Insiders Buying Westlake Chemical Partners And 2 Other Stocks
2 Apr 24
Recap: Oncternal Therapeutics Q4 Earnings
7 Mar 24
Oncternal Therapeutics Q4 2023 GAAP EPS $(3.110) Misses $(3.070) Estimate, Sales $297.000K Beat $137.500K Estimate
7 Mar 24
Press releases
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
18 Apr 24
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
15 Mar 24
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
7 Mar 24
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
6 Feb 24